{"entity":{"id":"nct07410494","kind":"trial","name":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","aka":["SELECT-CAR-NK"],"tldr":"A phase 1/2 trial in pancreatic cancer, run by Essen Biotech, now recruiting.","summary":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors is a phase 1/2, interventional study registered as NCT07410494 by Essen Biotech, with a registry enrolment figure of 85 participants, started 2026-02-01 and due to reach its primary completion in 2027-12-28. Interventions recorded: EB-SELECT Single-Target CAR-NK Cells; Dual-Target Antigen-Selected CAR-NK. Conditions listed: Cancer; Breast Cancer; Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer (Locally Advanced or Metastatic); Prostate Cancer - Recurrent; Pancreatic Ductal Adenocarcinoma (PDAC); Ovarian Cancer; Glioblastoma; Melanoma (Skin Cancer); Acute Myeloid Leukemia (AML); Non Hodgkin Lymphoma; Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma; Liver Cancer. Primary outcome: Incidence, type, and severity of adverse events (AEs), graded by CTCAE v5.0; Incidence of Dose-Limiting Toxicities (DLTs). Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07410494","url":"https://clinicaltrials.gov/study/NCT07410494"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07410494","phase":"1/2","setting":"A Phase 1/2, Open-Label, Biomarker-Driven Study of Allogeneic Donor-Derived CAR-NK Cells With Antigen Selection by Tissue Biopsy and/or Liquid Biopsy Profiling in Participants With Relapsed/Refractory Advanced Solid Tumors (Single-Target vs Dual-Target Strategy)","sponsor":"Essen Biotech","enrolled":85,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07410494/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}